AmpliMed Corporation

12 articles about AmpliMed Corporation

• AmpliMed Corporation Reports Results from AMP-019; A Randomized Double Blind Trial of Gemcitabine/Placebo vs. Gemcitabine/Amplimexon in Advanced Pancreatic Cancer

  7/12/2010

• AmpliMed Corporation Announces License Agreement with Handok Pharmaceuticals for Exclusive Rights to Cancer Therapeutic Amplimexon(R) in Korea

  9/10/2008

• AmpliMed Corporation to Present Clinical Data from Three Clinical Trials of Amplimexon® at American Society of Clinical Oncology Annual Meeting

  5/30/2008

• AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer

  5/1/2008

• AmpliMed Corporation Secures $8.5M In Additional Series B Financing; Oncology Drug Development Company To Use Funds To Achieve Milestones In Clinical Development

  11/28/2006

• AmpliMed Corporation To Present Positive Phase I Study Results For Amplimexon(R) (imexon for inj.) In Patients With Advanced Solid Tumors

  11/10/2006

• AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon plus Dacarbazine For Treatment Of Malignant Melanoma; Encouraging Data Presented At Perspectives In Melanoma X And The Third International Melanoma Research Congress In The Net

  9/14/2006

• AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon Plus Dacarbazine For Treatment Of Malignant Melanoma

  9/14/2006

• AmpliMed Corporation Initiates Phase I Clinical Study Of Benzimate In Patients With Advanced Refractory Cancer

  4/28/2006

• AmpliMed Corporation Begins Enrollment Of Phase I Trial Of Amplimexon In Patients With Multiple Myeloma

  3/27/2006

• European Commission Grants Orphan Drug Status For AmpliMed Corporation's Amplimexon(R) For The Treatment Of Ovarian Cancer

  1/11/2006

• Researchers To Present Positive Phase I Study Results For AmpliMed Corporation's(TM) Amplimexon(R) (imexon inj.) In Patients With Advanced Solid Tumors

  11/16/2005